FDA approves asundexian, the first factor XIa inhibitor to prevent repeat stroke
- On 9 November 2026 the FDA approved Bayer's Sunharbo (asundexian).
- It is for adults after a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk TIA.
- In OCEANIC-STROKE (12,327 patients) ischemic stroke fell to 6.2% vs 8.4% with placebo.
- Major bleeding was similar: 1.9% vs 1.7%.
The US Food and Drug Administration approved Sunharbo (asundexian), made by Bayer, on 9 November 2026. It is the first approved activated factor XI (XIa) inhibitor. It lowers the risk of another stroke in adults after a mild-to-moderate ischemic stroke that did not come from the heart, or after a high-risk transient ischemic attack.
What the trial showed
Approval rests on OCEANIC-STROKE, which enrolled 12,327 patients taking 50 mg once daily on top of standard antiplatelet therapy. Ischemic stroke occurred in 6.2% on asundexian versus 8.4% on placebo: about a 26% relative and 2.2% absolute reduction.
Bleeding
Major bleeding was similar (1.9% vs 1.7%), which matters because bleeding is the main worry with drugs that prevent clotting. Diarrhea was reported in 3.4% vs 2.8%.
Limits
The drug is not approved for atrial fibrillation and is used with antiplatelet therapy, not instead of it. Experts note its list price of about $748.50 a month may limit uptake.
Sources: FDA — Novel Drug Approvals 2026, AJMC, NeurologyLive
This story is relayed from the source named above; responsibility for its content rests with the original source.
FAQ
What is asundexian (Sunharbo)?
Asundexian is an oral drug from Bayer and the first activated factor XI (XIa) inhibitor approved by the FDA, used to lower the risk of a repeat stroke.
Who is asundexian for?
Asundexian is for adults after a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk TIA, taken together with antiplatelet therapy.
How much did asundexian reduce stroke?
In OCEANIC-STROKE, ischemic stroke occurred in 6.2% of patients on asundexian versus 8.4% on placebo, a relative reduction of about 26%.
Does asundexian raise bleeding risk?
In OCEANIC-STROKE, major bleeding was similar: 1.9% with asundexian versus 1.7% with placebo.
Is asundexian approved for atrial fibrillation?
No. The FDA approval of asundexian does not cover patients with atrial fibrillation.



